A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
EMBARK
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
1 other identifier
interventional
990
18 countries
301
Brief Summary
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2025
Typical duration for phase_3
301 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 3, 2025
CompletedStudy Start
First participant enrolled
March 18, 2025
CompletedFirst Posted
Study publicly available on registry
March 19, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 13, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 5, 2029
May 7, 2026
May 1, 2026
4 years
March 3, 2025
May 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Annualised rate of moderate or severe COPD exacerbations
The annualised moderate or severe COPD exacerbation rate (based on exacerbations reported by the investigator) up to 76 weeks treatment period compared to placebo.
Baseline up to 76 weeks
Secondary Outcomes (13)
Change from baseline in post-BD FEV1
From baseline to Week 52
Change from baseline in pre-dose/pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)
From baseline to Week 52
Change from baseline in the St. George's Respiratory Questionnaire (SGRQ) total score
From baseline over 52 weeks
Annualised rate of moderate or severe COPD exacerbations among participants with EOS ≥ 300 cells/µL collected during screening visit.
Baseline up to 76 weeks
Annualised rate of severe COPD exacerbations
Baseline up to 76 weeks
- +8 more secondary outcomes
Study Arms (3)
Dose 1 of Tezepelumab
EXPERIMENTALTezepelumab, SC, Q4W
Dose 2 of Tezepelumab
EXPERIMENTALTezepelumab, SC, Q4W
Matching Placebo
PLACEBO COMPARATORMatching placebo, SC, Q4W
Interventions
Eligibility Criteria
You may qualify if:
- ≥40 to ≤80 years old
- COPD diagnosis ≥1 year,
- Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC \<0.70 at screening
- Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1
- ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy
- EOS ≥ 150 cells/μL during screening
- CAT ≥15 at screening
- Former or current smokers ≥10 pack-years
You may not qualify if:
- Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD
- Asthma, incl. pediatric, or ACOS
- Any unstable disorder that can impact participants safety or study outcomes
- Tuberculosis requiring treatment within 12 months prior V2
- Malignancies current or past
- Concomitant therapies:
- Macrolides (less than 6 months)
- Systemic immuno-suppressive, -modulating medications
- LTOT \>4.0 L/min or O2 saturation \<89% despite LTOT
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Amgencollaborator
Study Sites (301)
Research Site
Foley, Alabama, 36535, United States
Research Site
Mobile, Alabama, 36609, United States
Research Site
Sheffield, Alabama, 35660, United States
Research Site
Phoenix, Arizona, 85012, United States
Research Site
Phoenix, Arizona, 85027, United States
Research Site
Tucson, Arizona, 85704, United States
Research Site
Garden Grove, California, 92844, United States
Research Site
Newport Beach, California, 92663, United States
Research Site
Torrance, California, 90502, United States
Research Site
Clearwater, Florida, 33765, United States
Research Site
Cutler Bay, Florida, 33157, United States
Research Site
Cutler Bay, Florida, 33189, United States
Research Site
DeBary, Florida, 32713, United States
Research Site
Gainesville, Florida, 32608, United States
Research Site
Homestead, Florida, 33032, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Miami, Florida, 33125, United States
Research Site
Miami, Florida, 33155, United States
Research Site
Miami, Florida, 33175, United States
Research Site
Orlando, Florida, 32807, United States
Research Site
Tampa, Florida, 33606, United States
Research Site
Tampa, Florida, 33607, United States
Research Site
Atlanta, Georgia, 30344, United States
Research Site
Lithonia, Georgia, 30038, United States
Research Site
Rincon, Georgia, 31326, United States
Research Site
Chicago, Illinois, 60611, United States
Research Site
Palos Hills, Illinois, 60465, United States
Research Site
Winfield, Illinois, 60190, United States
Research Site
Munster, Indiana, 46321, United States
Research Site
Baltimore, Maryland, 21201, United States
Research Site
Columbia, Maryland, 21045, United States
Research Site
North Dartmouth, Massachusetts, 02747, United States
Research Site
Farmington Hills, Michigan, 48336, United States
Research Site
Saint Cloud, Minnesota, 56303, United States
Research Site
St Louis, Missouri, 63103, United States
Research Site
Missoula, Montana, 59808, United States
Research Site
Papillion, Nebraska, 68046, United States
Research Site
Las Vegas, Nevada, 89106, United States
Research Site
Sewell, New Jersey, 08080, United States
Research Site
Toms River, New Jersey, 08755, United States
Research Site
Buffalo, New York, 14203, United States
Research Site
Buffalo, New York, 14215, United States
Research Site
Cortland, New York, 13045, United States
Research Site
Horseheads, New York, 14845, United States
Research Site
High Point, North Carolina, 27260, United States
Research Site
Kings Mountain, North Carolina, 28086, United States
Research Site
New Bern, North Carolina, 28562, United States
Research Site
Wilmington, North Carolina, 28412, United States
Research Site
Winston-Salem, North Carolina, 27103, United States
Research Site
Columbus, Ohio, 43213, United States
Research Site
Oklahoma City, Oklahoma, 73120, United States
Research Site
DuBois, Pennsylvania, 15801, United States
Research Site
Philadelphia, Pennsylvania, 19140, United States
Research Site
Rock Hill, South Carolina, 29732, United States
Research Site
Franklin, Tennessee, 37067, United States
Research Site
Johnson City, Tennessee, 37604, United States
Research Site
Dallas, Texas, 75254, United States
Research Site
Fort Worth, Texas, 76104, United States
Research Site
Houston, Texas, 77084, United States
Research Site
Houston, Texas, 77090, United States
Research Site
Humble, Texas, 77338, United States
Research Site
Kerrville, Texas, 78028, United States
Research Site
Mansfield, Texas, 76063, United States
Research Site
Clearfield, Utah, 84015, United States
Research Site
Morgantown, West Virginia, 26501, United States
Research Site
Cudahy, Wisconsin, 53110, United States
Research Site
Milwaukee, Wisconsin, 53295, United States
Research Site
Bragança Paulista, 12916-542, Brazil
Research Site
Brasília, 70200-730, Brazil
Research Site
Campinas, 13060-080, Brazil
Research Site
Chapecó, 89812-210, Brazil
Research Site
Curitiba, 80030-110, Brazil
Research Site
Jaú, 17201-130, Brazil
Research Site
Mossoró, 59603-020, Brazil
Research Site
Porto Alegre, 90035-903, Brazil
Research Site
Porto Alegre, 90480-000, Brazil
Research Site
Porto Alegre, 90560-003, Brazil
Research Site
Porto Alegre, 9061-000, Brazil
Research Site
Porto Alegre, 91350-200, Brazil
Research Site
Salvador, 40050-410, Brazil
Research Site
São José do Rio Preto, 15090-000, Brazil
Research Site
Vitória, 29062-110, Brazil
Research Site
Calgary, Alberta, T3R 1W7, Canada
Research Site
Vancouver, British Columbia, V5Z 1M9, Canada
Research Site
Ajax, Ontario, L1S 2J5, Canada
Research Site
Burlington, Ontario, L7N 3V2, Canada
Research Site
Scarborough Village, Ontario, M1P 2V5, Canada
Research Site
Toronto, Ontario, M5T 3A9, Canada
Research Site
Winchester, Ontario, K0C 2K0, Canada
Research Site
Windsor, Ontario, N8X-5A6, Canada
Research Site
Montreal, Quebec, H1T 2M4, Canada
Research Site
Montreal, Quebec, H3T 1E2, Canada
Research Site
Québec, Quebec, G1G 3Y8, Canada
Research Site
Québec, Quebec, G1V 4G5, Canada
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4, Canada
Research Site
Saint-Laurent, Quebec, H4R3C8, Canada
Research Site
Trois-Rivières, Quebec, G8T 7A1, Canada
Research Site
Saskatoon, Saskatchewan, S7N 0W8, Canada
Research Site
Concepción, 4070094, Chile
Research Site
Curicó, 3341643, Chile
Research Site
Quillota, 2260000, Chile
Research Site
Santiago, 7500010, Chile
Research Site
Santiago, 7500657, Chile
Research Site
Santiago, 7501126, Chile
Research Site
Santiago, 7750495, Chile
Research Site
Santiago, 8380453, Chile
Research Site
Talca, 3481349, Chile
Research Site
Anyang, 455099, China
Research Site
Beijing, 100020, China
Research Site
Beijing, 100191, China
Research Site
Changchun, 130021, China
Research Site
Changsha, 410008, China
Research Site
Changsha, 410015, China
Research Site
Changsha, 430033, China
Research Site
Chengdu, 610072, China
Research Site
Chengdu, 611130, China
Research Site
Chongqing, 400042, China
Research Site
Chongqing, 401320, China
Research Site
Fuzhou, 350031, China
Research Site
Guangzhou, 510000, China
Research Site
Guangzhou, 510150, China
Research Site
Guangzhou, 510163, China
Research Site
Guangzhou, 510515, China
Research Site
Haikou, 570311, China
Research Site
Hangzhou, 310005, China
Research Site
Hefei, 230061, China
Research Site
Hengyang, 421001, China
Research Site
Heze, 274099, China
Research Site
Hohhot, 750306, China
Research Site
Huizhou, 516002, China
Research Site
Jinan, 250013, China
Research Site
Jinan, 250021, China
Research Site
Jinhua, 321000, China
Research Site
Linhai, 317000, China
Research Site
Loudi, 417099, China
Research Site
Nanchang, 330006, China
Research Site
Nanchong, 637000, China
Research Site
Nanjing, 2100008, China
Research Site
Nanjing, 211100, China
Research Site
Nanning, 530000, China
Research Site
Nanning, 530021, China
Research Site
Pingxiang, 337055, China
Research Site
Qingdao, 266011, China
Research Site
Qingyuan, 511518, China
Research Site
Sanya, 572000, China
Research Site
Shanghai, 200040, China
Research Site
Shanghai, 200120, China
Research Site
Shanghai, 201199, China
Research Site
Shanghai, 310000, China
Research Site
Shantou, 515041, China
Research Site
Shenyang, 110004, China
Research Site
Shenzhen, 518020, China
Research Site
Shijiazhuang, 50051, China
Research Site
Suining Shi, 629000, China
Research Site
Taiyuan, 030001, China
Research Site
Taiyuan, 030032, China
Research Site
Taizhou, 318000, China
Research Site
Tianjin, 300050, China
Research Site
Wenzhou, 325027, China
Research Site
Wuhan, 430022, China
Research Site
Wuhan, 430030, China
Research Site
Xinxiang, 453100, China
Research Site
Xuzhou, 221000, China
Research Site
Xuzhou, 221009, China
Research Site
Yangzhou, 225001, China
Research Site
Yichang, 443003, China
Research Site
Yinchuan, 750001, China
Research Site
Yinchuan, 750004, China
Research Site
Zhangzhou, 363099, China
Research Site
Brandýs nad Labem, 250 01, Czechia
Research Site
Brno, 625 00, Czechia
Research Site
Jindřichův Hradec, 377 01, Czechia
Research Site
Lovosice, 410 02, Czechia
Research Site
Ostrava, 700 30, Czechia
Research Site
Pilsen, 301 00, Czechia
Research Site
Prague, 110 00, Czechia
Research Site
Prague, 15300, Czechia
Research Site
Teplice, 415 01, Czechia
Research Site
Varnsdorf, 407 47, Czechia
Research Site
København NV, 2400, Denmark
Research Site
Bendorf, 56170, Germany
Research Site
Berlin, 10787, Germany
Research Site
Haltern am See, 45721, Germany
Research Site
Hanover, D-30173, Germany
Research Site
Immenhausen, 34376, Germany
Research Site
Lübeck, 23552, Germany
Research Site
Marburg, 35037, Germany
Research Site
Rosenheim, 83022, Germany
Research Site
Wiesbaden, 65183, Germany
Research Site
Ahmedabad, 380053, India
Research Site
Ahmedabad, 380054, India
Research Site
Belagavi, 590010, India
Research Site
Coimbatore, 641028, India
Research Site
Dehradun, 248001, India
Research Site
Delhi, 110029, India
Research Site
Delhi, 110029, India
Research Site
Dwārka, 110075, India
Research Site
Faridabad, 121012, India
Research Site
Gurgaon, 122001, India
Research Site
Kochi, 682027, India
Research Site
Kolkata, 700053, India
Research Site
Kozhikode, 673008, India
Research Site
Lucknow, 226003, India
Research Site
Madurai, 625107, India
Research Site
Mysuru, 570002, India
Research Site
Nagpur, 440012, India
Research Site
Nagpur, 441108, India
Research Site
Pune, 411 018, India
Research Site
Telangana, 500004, India
Research Site
Vadodara, 391760, India
Research Site
Cona, 44124, Italy
Research Site
Florence, 50134, Italy
Research Site
Milan, 20122, Italy
Research Site
Montebelluna, 31044, Italy
Research Site
Naples, 80131, Italy
Research Site
Pavia, 27100, Italy
Research Site
Roma, 00128, Italy
Research Site
Sassari, 07100, Italy
Research Site
Telese Terme, 82037, Italy
Research Site
Tradate, 21049, Italy
Research Site
Alor Star, 5460, Malaysia
Research Site
Kajang, 43000, Malaysia
Research Site
Kota Kinabalu, 88200, Malaysia
Research Site
Kuala Lumpur, 50603, Malaysia
Research Site
Kuala Terengganu, 20400, Malaysia
Research Site
Kuantan, 25100, Malaysia
Research Site
Kuching, 93586, Malaysia
Research Site
Benito Juárez, 03650, Mexico
Research Site
Chihuahua City, 31000, Mexico
Research Site
Cuauhtémoc, 06700, Mexico
Research Site
Cuernavaca, 62290, Mexico
Research Site
Guadalajara, 44130, Mexico
Research Site
Mérida, 97130, Mexico
Research Site
Monterrey, 64310, Mexico
Research Site
Monterrey, 64460, Mexico
Research Site
Monterrey, 64465, Mexico
Research Site
Morelia, 58000, Mexico
Research Site
Oaxaca City, 68020, Mexico
Research Site
San Juan del Río, 76800, Mexico
Research Site
Tijuna, 22010, Mexico
Research Site
Veracruz, 91900, Mexico
Research Site
Zapopan, 45070, Mexico
Research Site
Zapopan, 45138, Mexico
Research Site
Iloilo City, 5000, Philippines
Research Site
Las Piñas, 1742, Philippines
Research Site
Manadaluyong City, 1552, Philippines
Research Site
Manila, 1000, Philippines
Research Site
Marilao, 3019, Philippines
Research Site
Quezon City, 1100, Philippines
Research Site
Quezon City, 1100, Philippines
Research Site
Tondo, 1012, Philippines
Research Site
Bialystok, 15-044, Poland
Research Site
Bydgoszcz, 85-231, Poland
Research Site
Bydgoszcz, 85-796, Poland
Research Site
Chrzanów, 32-500, Poland
Research Site
Karczew, 05-480, Poland
Research Site
Katowice, 40-648, Poland
Research Site
Kielce, 25-426, Poland
Research Site
Krakow, 31-513, Poland
Research Site
Lodz, 91-211, Poland
Research Site
Lublin, 20-011, Poland
Research Site
Ostróda, 14-100, Poland
Research Site
Piaseczno, 05-500, Poland
Research Site
Poznan, 60-693, Poland
Research Site
Pruszków, 05-800, Poland
Research Site
Płock, 09-407, Poland
Research Site
Humenné, 066 01, Slovakia
Research Site
Košice, 04011, Slovakia
Research Site
Levice, 93401, Slovakia
Research Site
Martin, 03659, Slovakia
Research Site
Trnava, 91701, Slovakia
Research Site
Anyang-si, 14068, South Korea
Research Site
Daegu, 42415, South Korea
Research Site
Iksan-si, 54538, South Korea
Research Site
Jeonju, 54907, South Korea
Research Site
Seoul, 06591, South Korea
Research Site
Seoul, 06973, South Korea
Research Site
Seoul, 08308, South Korea
Research Site
Seoul, 135-710, South Korea
Research Site
Seoul, 143-729, South Korea
Research Site
Seoul, 150-713, South Korea
Research Site
Uijeongbu-si, 11765, South Korea
Research Site
Wŏnju, 26426, South Korea
Research Site
Barakaldo, 48903, Spain
Research Site
Barcelona, 08036, Spain
Research Site
Granada, 18014, Spain
Research Site
Madrid, 28007, Spain
Research Site
Málaga, 29010, Spain
Research Site
Palma de Mallorca, 07010, Spain
Research Site
Pamplona, 31008, Spain
Research Site
Seville, 41013, Spain
Research Site
Valencia, 46010, Spain
Research Site
Bradford, BD9 6RJ, United Kingdom
Research Site
Brighton, BN2 1ES, United Kingdom
Research Site
Cottingham, HU16 5JQ, United Kingdom
Research Site
Glasgow, G12 0YN, United Kingdom
Research Site
Halifax, HX3 0PW, United Kingdom
Research Site
Leeds, LS9 7TF, United Kingdom
Research Site
Portsmouth, PO6 3LY, United Kingdom
Research Site
Tyne and Wear, NE29 8NH, United Kingdom
Research Site
Wakefield, WF1 4DG, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dave Singh, MD
Division of Infection, Immunity & Resp Medicine, The University of Manchester, United Kingdom
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Double-blinded
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 3, 2025
First Posted
March 19, 2025
Study Start
March 18, 2025
Primary Completion (Estimated)
March 13, 2029
Study Completion (Estimated)
June 5, 2029
Last Updated
May 7, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.